MRNA Moderna Therapeutics: Business Value

Moderna Therapeutics - graphic logo of issuer MRNA

The share price retrospective of Moderna, Inc. (MRNA) illustrates the efficiency of a unified mRNA environment, where a programmable synthesis method provides a strong moat against competitors. The current metric stands at 79178.09. The business is currently shifting its focus from COVID-related products toward rapidly evolving cancer vaccines and RSV. As a leader in digital medicine, Moderna, Inc. (MRNA) develops drugs with computational precision, reprogramming cells for cancer therapy.

MRNA (modernatx.com) Total Company Value history from 11/23/2025 to 10/28/2026

Moderna, Inc. (MRNA) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Performance Chart Moderna Inc|MRNA - Price Target Chart
- market capitalization data:
Market Capitalization Moderna|MRNA - Enterprise Value
- book capitalization data:
Book Value per Share Moderna|MRNA - Company Book Value|Market Capitalization to Net Assets modernatx.com|MRNA - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Moderna, Inc.|MRNA - Long-Term Debt to Capital|Short-Term Debt to Capital modernatx.com|MRNA - Company Debts|Debt to Net Assets Ratio Moderna|MRNA - Company Long-Term Debt|Company Current Liabilities Moderna
Comprehensive company analysis:Moderna Inc (MRNA)
Original product of Moderna, Inc.

Moderna, Inc. (MRNA) strategic alliances in mRNA technologies are generating substantial capital that requires a comprehensive valuation based on the combination of market capitalization and net debt. By analyzing the evolution of the business value, an investor can determine the actual buyout price of the company, where daily price action converges with quarterly cash flow dynamics, enabling the real-time assessment of fundamental risks without waiting for financial reports.

Competitor analysis for Moderna, Inc.

Summit Therapeutics plc - Value Adjusted for Debt and Cash|Vaxcyte Corp (PCVX) - Total Company Value|TARS - Business Value|CRMD: Enterprise Value|MCRB (serestherapeutics.com) - Enterprise Value|Total Company Value Spero Therapeutics, Inc. SPRO|Full Business Value Scynexis|AN2 Therapeutics, Inc. (ANTX) - Enterprise Value|Value Adjusted for Debt and Cash polypid.com (PYPD)|Enterprise Value LSB (LakeShore Biopharma Co.)|Iterum Therapeutics PLC - Enterprise Value|Total Company Value BiomX Ltd (PHGE)|SNGX: Value Adjusted for Debt and Cash|SXTP (60degreespharma.com) - Total Company Value|oragenics.com (OGEN) - Real Price to Acquire Entire Company|ONCO (Onconetix, Inc.) - Enterprise Value|Enterprise Value opgen.com (OPGN)